ALFA Finder| Revenue growth | 2% YoY in Q1 FY27. |
|---|---|
| Margins | EBITDA margin at 27%; PAT margin at 20%. |
| Demand visibility | Strong growth in Specialized Manufacturing (+41% YoY) and Bio-processing (+30%). |
Growth
Revenue +2% YoY to ₹1,898 mn; PAT -5% YoY to ₹386 mn; EBITDA margin at 27%.
Outlook
Focusing on Bio-Catalysis for APIs and expanding Probiotics in human/animal nutrition. Maintaining 400+ proprietary products and 15+ patents.
Risks
Human nutrition segment (-7%) and animal nutrition (-3%) saw YoY de-growth. Sequential EBITDA dropped 19%.
Last quarter's promises, checked
Delivered
- Guided double-digit growth → delivered 17% annual revenue growth (= BEAT)
- Guided steady margins → delivered 31% EBITDA margin (= BEAT)
- Guided R&D center operational H2 FY26 → delivered operational status (= BEAT)
Partly delivered
- Guided EU approval for anti-inflammatory products → dossiers filed, still pending (= PARTIAL)
Missed
- Guided U.S. market growth → delivered 11% revenue decline in INR terms (= MISS)
- Guided Human Nutrition growth → delivered 7% YoY de-growth in Q1 FY27 (= MISS)
- Guided Animal Nutrition growth → delivered 3% YoY de-growth in Q1 FY27 (= MISS)
Investor Presentation filed with NSE, NSE: ADVENZYMES. Summary written with AI assistance from the document.
Advanced Enzyme Technologies Ltd: key numbers
- Share price
- ₹283.50
- Market cap
- ₹3,175 Cr
- Revenue (annual)
- ₹745.8 Cr
- Net profit (annual)
- ₹168.7 Cr
- P/E (TTM)
- 18.6×Sector 43.8×
- Promoter holding
- 43.56%+0.32% QoQ
- FII holding
- 26.64%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Advanced Enzyme Technologies Ltd
All →Advanced Enzyme Technologies Earnings Call Transcript: Key Takeaways
Clean headline: revenue +16% YoY, EBITDA 34%, PAT +14%. Growth leans on deferred sales and rising top-10 customer concentration (46%). US recovery is only hoped for.
Advanced Enzyme Technologies Promoter Reclassification
Advanced Enzyme Technologies applied to exchanges to reclassify 13 promoter group members as public under Regulation 31A. They hold 59,000 shares combined, about 0.05%.
Advanced Enzyme Technologies Investor Presentation: Key Takeaways
Q2 FY27 consolidated revenue ₹2,145mn (+16% YoY), EBITDA ₹721mn (+20%, 34% margin), PAT ₹512mn (+14%). H1 revenue +10%, PAT +5%. Industrial bio-processing and animal nutrition lead growth.
Advanced Enzyme Technologies Results Update
Advanced Enzyme Technologies issued a press release highlighting unaudited Q2 and half-year FY27 results. Revenue and profit grew year-on-year, with EBITDA and PAT margins reported.
Advanced Enzyme Technologies Q2 FY27 Results: Net Profit ₹51.2 Cr, Up 14.5% YoY
Advanced Enzyme Technologies Ltd reported revenue from operations of ₹214.5 Cr (+16.3% YoY) and net profit of ₹51.2 Cr (+14.5% YoY) for Q2 FY27.
- Key figure
- Net profit ₹51.2 Cr · +14.5% YoY
Advanced Enzyme Technologies Capital Structure Change
Advanced Enzyme closed its buyback after purchasing 2,410,906 shares for ₹69.70 Crore. Closure took effect October 30, 2026, ahead of the scheduled period.
- Value
- ₹69.70 Cr
- Execution
- August 14, 2026 to October 30, 2026